Generex Biotechnology

Generex Biotechnology

Generex is a biotechnology and pharmaceutical company that develops and commercializes drug delivery systems and technologies for metabolic and immunological diseases.

Generex is a biotechnology and pharmaceutical company that develops and commercializes drug delivery systems and technologies for metabolic and immunological diseases. The company was founded in 1983 in Miramar Beach, Florida, United States.

The company also looks to make strategic business decisions that allows them to provide management services, organize a network of pharmacies, clinical laboratories, and medical companies.

COVID-19

Along with its subsidiary, NuGenerex Immune-Oncology, Generex Biotechnology Corporation have launched a development platform for the development of a COVID-19 vaccine.

The company is looking to launch their vaccine using a li-key vaccine platform. The company has also signed a contract with EpiVax to use their tools in order to predict epitopes that will be used to generate peptide vaccines against the coronavirus. The companies together have identified hotspots in the amino acid sequences of the COVID-19 virus. The company will send their amino acids to China for the testing of the peptides in blood samples.

Timeline

August 10, 2012
Generex Biotechnology raises a $750,000 venture round.
February 1, 2012
Generex Biotechnology raises a $2,000,000 venture round.
January 25, 2012
Generex Biotechnology raises a $3,600,000 private equity.
January 25, 2011
Generex Biotechnology raises a $3,000,000 venture round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Generex Biotechnology Private equity, January 2012
3,600,000
January 25, 2012
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

David Brusegard

COO

Eric von Hofe

Vice President

Geral Bernstein

Medical Affairs

Mark Fletcher

President, CEO

Stephen Fellows

CFO

Further reading

Title
Author
Link
Type
Date

COMPANY

Web

Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media

Web

March 11, 2020

Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic - EpiVax, Inc. - Informatics and Immunology

Web

March 4, 2020

Documentaries, videos and podcasts

Title
Date
Link

CoronaVirus Cure (Joseph Moscato & Dr. Eric Von Hofe of Generex Biotechnology Corporation) Ep. #040

Companies

Company
CEO
Location
Products/Services

Generex

Mark Fletcher

Miramar Beach, Florida, United States

Biotechnology, vaccinations

News

Title
Author
Date
Publisher
Description
BioSpace
November 18, 2020
BioSpace
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO)

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.